Baker Institute experts blog on opportunities for the U.S. and Mexico to jointly address the neglected tropical diseases found among the poorest people living in both countries.
Peter J. Hotez, Jennifer R. Herricks, Kirstin R.W. MatthewsSeptember 28, 2015
In this commentary, the authors examine the roots of the United States’ reluctance to embrace universal health care, concluding that it "is neither sound nor ethical in a nation that promulgates fairness and equal opportunity" to deny coverage.
In physics, extensive collaborations, access to colleagues’ data and rigorous peer review make it extremely difficult for individual researchers to bend the rules. Furthermore, physics does not harbor the types of ethical minefields characteristic of the biosciences. No thorny questions arise pertaining to human or animal life, nor do physicists commonly grapple with the ethical haze of intellectual property when patents and money are at stake. Things seem to be black and white in physics. But are they?
Elaine Howard Ecklund, Kirstin R.W. MatthewsJune 1, 2015
It is inconceivable to imagine our nation today without the gains of the Civil Rights Act. It is impossible to understand why the issue was so divisive then, since it is such an obvious right and moral proposition. Similarly, let us hope we will look back at the Affordable Care Act 20 years from now and wonder why it was such a contentious topic in 2014.
Cancer drug shortages are almost uniquely associated with generic drugs (small profit margins) and rarely with patented drugs (large profit margins). They are common in the U.S., but uncommon in Europe and elsewhere, where generic drug prices are on average higher than in the U.S. This suggests the main cause of drug shortages is economic.
Baker Institute health policy experts Hagop M. Kantarjian and Vivian Ho explain why Texas, which holds the notorious record of the highest rate of uninsured citizens in the U.S., should follow many Republican-led states that are now reconsidering the Medicaid expansion program under Obamacare.
In a recent commentary, Baker Institute science and technology policy experts described two international court cases that aimed to define “research” — and that ultimately arrived at two different answers.
“What makes this interesting is that the courts’ definition of ‘research’ was based on politics — what the court wanted the end result to be,” said Kirstin Matthews, the institute’s fellow in science and technology policy. To reach a decision prohibiting human embryonic stem cell (hESC) patents, the EU court ruled that “research” occurs in a continuum. To reach a decision supporting federal funding of stem cell research, the U.S. court ruled that “research” involves a specific project.